Patents by Inventor Anuradha Roy

Anuradha Roy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220105114
    Abstract: The disclosure provides methods of treating cancer by selectively inhibiting p-S552-?-catenin, p-T217-?-catenin, T332-?-catenin, and/or p-S675-?-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 7, 2022
    Inventors: Rajeswari KASI, Linheng Ll, Xiuling LU, John M. PERRY, Gurusingham Sitta SITTAMPALAM, Anuradha ROY, Xi C. HE
  • Patent number: 11173173
    Abstract: The disclosure provides methods of treating cancer by selectively inhibiting p-S552-?-catenin, p-T217-?-catenin, p-T332-?-catenin, and/or p-S675-?-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 16, 2021
    Assignees: UNIVERSITY OF CONNECTICUT, UNIVERSITY OF KANSAS, STOWERS INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Rajeswari Kasi, Linheng Li, Xiuling Lu, John M. Perry, Gurusingham Sitta Sittampalam, Anuradha Roy, Xi C. He
  • Patent number: 11062327
    Abstract: An electronic platform to measure a maturity or level of an entity in view of regulatory and business risks relating to regulatory compliance. The methods and systems can collect various data (e.g., regulatory agency reports, regulatory agency warning letters (e.g. FDA warning letters), internal and vendor company audit results, fines and settlement information, country business risks, regulatory agency product recalls, etc.) from various different data sources. The collected information is analyzed using machine learning techniques to determine a risk compliance level or score for one or more of an entity's companies, functions, control types, and locations arising from regulatory audit non-conformances. The risk compliance scores can be used to generate a risk prediction and identify one or more actions to be taken by the entity to improve or increase an associated compliance level.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: July 13, 2021
    Assignee: Xybion Corporation Inc.
    Inventors: Kamal Biswas, Pradip K. Banerjee, Robert J. Friedman, Avanish Ojha, Anuradha Roy
  • Publication number: 20210113597
    Abstract: The present disclosure provides, inter alia, methods for treating cancers including leukemia using low doses of an anthracycline such as doxorubicin.
    Type: Application
    Filed: June 26, 2020
    Publication date: April 22, 2021
    Inventors: Linheng Li, John M. Perry, Fang Tao, Xi C. He, Anuradha Roy, Scott J. Weir, Tara Lin
  • Publication number: 20200273046
    Abstract: An electronic platform to measure a maturity or level of an entity in view of regulatory and business risks relating to regulatory compliance. The methods and systems can collect various data (e.g., regulatory agency reports, regulatory agency warning letters (e.g. FDA warning letters), internal and vendor company audit results, fines and settlement information, country business risks, regulatory agency product recalls, etc.) from various different data sources. The collected information is analyzed using machine learning techniques to determine a risk compliance level or score for one or more of an entity's companies, functions, control types, and locations arising from regulatory audit non-conformances. The risk compliance scores can be used to generate a risk prediction and identify one or more actions to be taken by the entity to improve or increase an associated compliance level.
    Type: Application
    Filed: February 26, 2019
    Publication date: August 27, 2020
    Inventors: Kamal Biswas, Pradip K. Banerjee, Robert J. Friedman, Avanish Ojha, Anuradha Roy
  • Publication number: 20180207184
    Abstract: The disclosure provides methods of treating cancer by selectively inhibiting p-S552-?-catenin, p-T217-?-catenin, p-T332-?-catenin, and/or p-S675-?-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.
    Type: Application
    Filed: July 28, 2016
    Publication date: July 26, 2018
    Inventors: Rajeswari KASI, Linheng Ll, Xiuling LU, John M. PERRY, Gurusingham Sitta SITTAMPALAM, Anuradha ROY, Xi C. HE
  • Patent number: 9476870
    Abstract: The invention relates to the fields of screening assays, compounds, and methods for altering gene expression and protein levels. In particular, the invention includes assays to screen for agents capable of modulating gene expression in a UTR-dependent manner and agents capable of modulating gene expression.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: October 25, 2016
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Liangxian Cao, Nikolai Naryshkin, Charles Romfo, Matthew C. Pellegrini, Anuradha Roy, Panayiota Trifillis, Christopher R. Trotta
  • Patent number: 8962624
    Abstract: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: February 24, 2015
    Assignee: University of Kansas
    Inventors: Emily Scott, Anuradha Roy
  • Publication number: 20140045851
    Abstract: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicant: University of Kansas
    Inventors: Emily Scott, Anuradha Roy
  • Patent number: 8598165
    Abstract: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: December 3, 2013
    Assignee: University of Kansas
    Inventors: Emily Scott, Anuradha Roy
  • Publication number: 20090137592
    Abstract: A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.
    Type: Application
    Filed: November 24, 2008
    Publication date: May 28, 2009
    Inventors: Emily Scott, Anuradha Roy